{"id":"cd11301-0-03","_chembl":null,"modality":"Small molecule","_dailymed":null,"_scrapedAt":"2026-03-28T03:56:50.885Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123788,"model":"claude-sonnet-4-5-20250929"},"description":"CD11301 0.03% is an investigational topical agent in Phase 2 development by Galderma R&D for dermatological conditions. The molecular target and specific mechanism of action have not been publicly disclosed. As a dermatology-focused compound, it is likely being evaluated for inflammatory or other skin disorders.","indications":{"approved":[{"status":"investigational","condition":"Dermatological condition (unspecified)","patientPopulation":"Unknown"}]},"trialDetails":[{"nctId":"NCT03292406","phase":"PHASE2","title":"A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2017-12-19","conditions":"Cutaneous T Cell Lymphoma","enrollment":86}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":267593,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"CD11301 0.03%","genericName":"CD11301 0.03%","companyName":"Galderma R&D","companyId":"galderma-r-d","firstApprovalDate":"","aiSummary":"","enrichmentLevel":1,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}